Unravel Biosciences

This International Women’s Day, we acknowledge the women fighting #RareDisease every day. Women are 10x more likely to be caregivers but are not recognized for it. Caregivers often balance the demands of caring for an individual with rare disease with their own professional and personal demands, while receiving minimal recognition. The courage, dedication, and perseverance of caregivers inspires us at Unravel Biosciences. Leave a comment below to thank the women in your life. ?? #InternationalWomensDay #RareDisease #DrugDiscovery #Therapeutics

Tune in to this groundbreaking episode of Unraveling Rare as we welcome Anna Pfalzer, CSO of COMBINEDBrain, Kathleen Boychuck, President of the The MED13L Foundation, J. Michael Graglia, CEO & Founder of the SynGAP Research Fund (SRF) for SYNGAP1-Related Disorders, and our very own Richard Novak, CEO & Co-Founder of Unravel Biosciences to discuss how our new partnership will shape the future of rare disease treatment and research. Don’t miss these insights into our collective journey towards a better tomorrow. https://lnkd.in/gHEGunfr #raredisease #combinedbrain #drugdevelopment

Unravel Biosciences is thrilled to announce our landmark collaboration with COMBINEDBrain to conduct large-scale drug discovery across more than 100 COMBINEDBrain patient advocacy group members. The objective of our partnership is to identify molecular similarities and shared mechanisms across rare diseases to create a more efficient model for drug development in the #raredisease space but to do this we need data from #patients. This partnership will help us generate data directly from patients and their matched healthy control and enable us to draw connections between more rare diseases than ever. Accessing rare disease patients across the globe can be challenging, but using our nasal swab sample collection kits, the COMBINEDBrain team will use their streamlined biosampling network to collect samples in a time- and cost-efficient manner – at rare disease conferences and showcases and even in patients' homes. All data will enable collaborating research teams, and Unravel will drive initial commercial development to bring effective treatments to patients with high unmet need, many disorders at a time. We look forward to changing the drug development paradigm with the dedicated COMBINEDBrain team and COMBINEDBrain consortium partners. Read more about our collaboration here https://lnkd.in/em5w7vhN and check out COMBINEDBrain at https://combinedbrain.org/. #RareDiseaseDay #RareDisease #DrugDiscovery #Therapeutics

On Rare Disease Day, Unravel Biosciences would like to reflect on the support that our work has received from the rare disease community. This community is made up of patients, advocates, clinicians, scientists, investors, and more, all who contribute something unique and important to the rare disease space. We are proud and grateful to work toward transforming the paradigm of drug development and giving the rare disease community the recognition and therapies that it deserves. #RareDiseaseDay #RareDisease #Therapeutics #DrugDiscovery

Unravel Biosciences is thrilled to announce our landmark collaboration with COMBINEDBrain to conduct large-scale drug discovery across more than 100 COMBINEDBrain patient advocacy group members. The objective of our partnership is to identify molecular similarities and shared mechanisms across rare diseases to create a more efficient model for drug development in the #raredisease space but to do this we need data from #patients. This partnership will help us generate data directly from patients and their matched healthy control and enable us to draw connections between more rare diseases than ever. Accessing rare disease patients across the globe can be challenging, but using our nasal swab sample collection kits, the COMBINEDBrain team will use their streamlined biosampling network to collect samples in a time- and cost-efficient manner – at rare disease conferences and showcases and even in patients' homes. All data will enable collaborating research teams, and Unravel will drive initial commercial development to bring effective treatments to patients with high unmet need, many disorders at a time. We look forward to changing the drug development paradigm with the dedicated COMBINEDBrain team and COMBINEDBrain consortium partners. Read more about our collaboration here https://lnkd.in/em5w7vhN and check out COMBINEDBrain at https://combinedbrain.org/. #RareDiseaseDay #RareDisease #DrugDiscovery #Therapeutics

#RareDiseaseDay is approaching, so Unravel would like to share an overview of our rareSHIFT? platform. At Unravel, we recognize that rare disease patients are often left behind in the drug development space due to high financial risk.? We use rareSHIFT? to identify shared treatment responses and mechanisms across rare diseases to increase the efficiency of drug development.? RareSHIFT? has 40 + programs involving a variety of rare diseases. Check out an overview of rareSHIFT?, or watch at https://lnkd.in/eT-_W9yh, to see if your goals align with the rareSHIFT? program. You can reach out to [email protected] with any questions or leave a comment below. ?? #RareDiseaseDay #RareDisease #Therapeutics #DrugDiscovery?

The impact of our laboratory team is felt across our partnerships and within our team. We are grateful to have scientists and researchers who draw inspiration from our vision to see all patients have access to safe and effective treatments.? Check out what motivates some of our scientists and researchers as they work on our SquishyWare? in vivo models.? #RareDiseaseDay #RareDisease #Therapeutics #DrugDiscovery?

How do you know if a drug will work? You test it! At Unravel, we develop our in vivo model, SquishyWare?, using CRISPR-edited Xenopus, or tadpoles. SquishyWare? allows us to validate our drug discovery predictions and are quick and easy to develop—a high-throughput model. They are excellent models for various clinically relevant metrics, such as seizures. Check out some more metrics below! #RareDisease #RareDiseaseMonth #DrugDiscovery #Therapeutics

We get asked a wide variety of questions about our rareSHIFT? program because it is so different from traditional drug development. It aims to develop treatment options for more than one orphan disorder at a time by unraveling molecular similarities in disease pathology and treatment. Read more below! To learn more about rareSHIFT? check out our website’s FAQ page: https://lnkd.in/dSfnwHSY #RareDisease #RareDiseaseMonth #Therapeutics #DrugDiscovery

Did you catch?Richard Novak's presentation at the Precision Medicine World Conference yesterday? Here's a highlight. #AI #RareDisease #Therapeutics #DrugDiscovery